Current Report Filing (8-k)
January 31 2017 - 7:45AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): January 31, 2017
SERES THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-37465
|
|
27-4326290
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
200 Sidney Street
Cambridge, MA 02139
(Address of principal executive offices) (Zip Code)
(617)
945-9626
(Registrants telephone number, include area code)
N/A
(Former Name or
Former Address, if Changed Since Last Report)
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Item 7.01.
|
Regulation FD Disclosure.
|
On January 31, 2017, Seres Therapeutics, Inc. (the
Company) will host an investor conference call and live webcast to present the results of its
in-depth
analyses of the previously reported
SER-109
Phase 2,
8-week
clinical study data in patients with multiply recurrent
Clostridium difficile
infection. A copy of the slide presentation from this conference call is attached as Exhibit 99.1 to this Current Report on
Form
8-K.
The slide presentation will be archived for approximately 30 days in the Investors & Media portion of the Companys website at
www.serestherapeutics.com
.
The information in Item 7.01 of this Current Report on Form
8-K,
including Exhibit 99.1 attached
hereto, is intended to be furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section,
nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. The Company undertakes no obligation to update,
supplement or amend the materials attached hereto as Exhibit 99.1.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits.
|
|
|
Exhibit
No.
|
|
Exhibit Description
|
|
|
99.1
|
|
SER-109
Phase 2 Study Analysis Slide Deck for Presentation on January 31, 2017
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
SERES THERAPEUTICS, INC.
|
|
|
|
|
Date: January 31, 2017
|
|
|
|
By:
|
|
/s/ Eric D. Shaff
|
|
|
|
|
Name:
|
|
Eric D. Shaff
|
|
|
|
|
Title:
|
|
Executive Vice President and Chief Financial Officer
|
EXHIBIT INDEX
|
|
|
Exhibit
No.
|
|
Exhibit Description
|
|
|
99.1
|
|
SER-109
Phase 2 Study Analysis Slide Deck for Presentation on January 31, 2017
|
Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
From Apr 2023 to Apr 2024